Evidence map›Paper›PMID 40841465›Full record

ArticleMolecular diversity2026

Synthesis and preclinical evaluation of an

Wenjun Miao, Meixian Yang, Zhiping Peng, Zhu Xia, Xiaoyang Zhang, Yi Chen, Jianhua Jia

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjun Miao *Department of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Meixian Yang *Department of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Zhiping PengDepartment of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Zhu XiaDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Xiaoyang ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Yi ChenDepartment of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Jianhua JiaDepartment of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China. jianhuajia@cqmu.edu.cn.

Funding

the Natural Science and Technology Research Project of Chongqing Education Commission KJQN202100416
6 · The paper itself

Abstract

Cyclooxygenase-2 (COX-2) plays vital roles in promoting angiogenesis, tissue invasion, and resistance to apoptosis, so it has become an attractive biomarker for imaging and therapy of cancer. Numerous radio-tracers for detection of COX-2 in vivo have been reported, but no one has been successfully applied in clinic. In this study, the radiosynthesis and evaluation of [

Indexed as

Cyclooxygenase 2Fluorine RadioisotopesPyrrolesRadiopharmaceuticalsAnimalsFemaleHumansMCF-7 CellsMicePositron-Emission TomographyRadiochemistryTissue DistributionCyclooxygenase 2Fluorine-18Fluorine RadioisotopesPyrrolesRadiopharmaceuticals18F-labeled 1,5-diarylpyrrole derivativeCancerCOX-2 imaging agentRadio-tracer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.